Clinical Trials Logo

Clinical Trial Summary

The goal of this clinical trial is to assess the feasibility and clinical value of acetylcholine (ACH) rechallenge after intracoronary verapamil +- nitroglycerine in a patient cohort with angina and non-obstructive coronary arteries (ANOCA). The main questions it aims to answer are: - to determine the efficacy of these drugs in treating ACH-induced coronary artery spasm - to determine the efficacy of these drugs in preventing ACH-induced coronary artery spasm The ACH rechallenge will take place during the index coronary function tests in patients with proven ACH-induced vasospastic angina. The study is considered a feasibility study, no control arm is included.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT05618132
Study type Interventional
Source University Hospital, Antwerp
Contact Tijs Bringmans
Phone +32 3 821 3843
Email tijs.bringmans@uza.be
Status Recruiting
Phase N/A
Start date January 9, 2023
Completion date June 1, 2024

See also
  Status Clinical Trial Phase
Recruiting NCT02845531 - Implantable Cardioverter Defibrillator Versus Optimal Medical Therapy In Patients With Variant Angina Manifesting as Aborted Sudden Cardiac Death Phase 4
Withdrawn NCT02790528 - Statin Therapy In Patients With Vasospastic Angina Phase 4
Active, not recruiting NCT01318629 - Angina in Non Coronary Artery Disease N/A
Recruiting NCT00620204 - Efficacy Study of Atorvastatin to Treat Variant Angina Phase 4
Active, not recruiting NCT03477890 - Coronary Microvascular Function and CT Coronary Angiography (CorCTCA) N/A
Withdrawn NCT02932553 - BVS Implantation in Patients With Variant Angina and MODerate Coronary Artery Disease Phase 4